500 myeloma patients to be tracked in Real-World immunotherapy study
NCT ID NCT07296627
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 500 Chinese patients newly diagnosed with multiple myeloma who are receiving immunotherapy as their first treatment. Researchers will collect data on which treatments are used and how well they work over one year, with longer follow-up for survival. The goal is to improve personalized treatment decisions in real-world clinical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide real-world evidence to guide better treatment decisions for multiple myeloma patients in China.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One-shot CAR-T therapy takes on stem cell transplant for multiple myeloma
- Engineered immune cells take aim at multiple myeloma from the start
- New hope for myeloma: experimental drug combo aims to beat standard care
- New drug cocktail shows promise against blood cancer
- New scan could spot hidden myeloma earlier